Equities research analysts expect Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) to report $0.91 earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for Valeant Pharmaceuticals International’s earnings. The lowest EPS estimate is $0.83 and the highest is $1.02. Valeant Pharmaceuticals International posted earnings per share of $1.55 during the same quarter last year, which would suggest a negative year over year growth rate of 41.3%. The company is expected to issue its next earnings results before the market opens on Tuesday, November 7th.

According to Zacks, analysts expect that Valeant Pharmaceuticals International will report full-year earnings of $3.68 per share for the current year, with EPS estimates ranging from $3.39 to $4.04. For the next year, analysts forecast that the company will report earnings of $3.61 per share, with EPS estimates ranging from $3.04 to $4.30. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Valeant Pharmaceuticals International.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. The firm had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.88) EPS.

VRX has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a report on Thursday, October 12th. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Piper Jaffray Companies set a $14.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a “sell” rating in a report on Sunday, October 22nd. Vetr raised shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $12.46 price objective on the stock in a report on Monday, September 18th. Finally, Cantor Fitzgerald set a $23.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a “buy” rating in a report on Wednesday, August 16th. Five analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $17.56.

Shares of Valeant Pharmaceuticals International (NYSE VRX) traded down $0.60 during midday trading on Friday, hitting $11.33. 3,768,450 shares of the stock were exchanged, compared to its average volume of 10,561,350. The stock has a market capitalization of $3,854.64, a PE ratio of 1.66 and a beta of -0.40.

WARNING: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/03/valeant-pharmaceuticals-international-inc-vrx-expected-to-post-earnings-of-0-91-per-share.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average price of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.87% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Riggs Asset Managment Co. Inc. increased its position in Valeant Pharmaceuticals International by 118.2% in the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock worth $119,000 after purchasing an additional 4,512 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 2,763 shares during the last quarter. OLD Mutual Customised Solutions Proprietary Ltd. increased its position in Valeant Pharmaceuticals International by 357.7% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,900 shares of the specialty pharmaceutical company’s stock worth $131,000 after purchasing an additional 9,300 shares during the last quarter. NEXT Financial Group Inc increased its position in Valeant Pharmaceuticals International by 6.2% in the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock worth $178,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Architects Inc increased its position in Valeant Pharmaceuticals International by 10.5% in the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock worth $183,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 50.21% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get a free copy of the Zacks research report on Valeant Pharmaceuticals International (VRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.